First patient treated in trial turning back cellular age to tackle glaucoma
TL;DR
The first participant has been treated in a landmark trial testing partial cellular reprogramming—activating three genes to make aged cells behave younger—in hopes of regenerating optic nerve neurons and treating glaucoma; safety is the primary focus, with low—but not zero—risk of cancer, and results will determine viability for broader use.
- World-first: therapy to make cells young again given to a person Nature
- The first-ever reverse-aging drug was just injected into a human Business Insider
- Longevity Startup Doses First Human in Bid to Reverse Age-Related Sight Loss WIRED
- Re-Setting the Epigenetic Clock To Reverse Cellular Aging Technology Networks
- Life Bio reaches first clinical milestone for OSK therapy Longevity.Technology
Want the full story? Read the original reporting
Read on Nature